On November 5, HUTCHMED rose 5.67% in Regular Trading, trading at HK$23.12, with turnover of HK$58.69 million.
The move followed the company’s announcement that the US FDA granted orphan drug designation to its oral Syk inhibitor sovleplenib for the treatment of autoimmune hemolytic anemia, adding a new regulatory milestone for the asset.
According to the company disclosure released on November 5, this is sovleplenib’s second US orphan drug designation after a prior designation granted in late October for primary immune thrombocytopenia. The update broadens the product’s rare-disease positioning and reinforces recent pipeline momentum, following other regulatory and business developments including the completion of its ex-China licensing transaction with GSK for HMPL-A830 and the US NDA submission by its partner for the ORPATHYS-TAGRISSO combination.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments